Akoya Biosciences, Inc.

Q: Mar 31 2025

FY: Dec 31 2024

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Q: Mar 31 2024

FY: Dec 31 2023

Q: Sep 30 2023

Q: Jun 30 2023

Q: Mar 31 2023

FY: Dec 31 2022

Q: Sep 30 2022

Q: Jun 30 2022

Q: Mar 31 2022

FY: Dec 31 2021

Q: Sep 30 2021

Q: Jun 30 2021

Q: Mar 31 2021

Termination of a Material Definitive Agreement

Submission of Matters to a Vote of Security Holders

Other Events

Other Events

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Other Events

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

2.02,9.01

8.01

2.02,5.02,9.01

5.07

2.02,9.01

2.02,9.01

5.02,7.01,9.01

2.02,9.01

2.02,9.01

Certification of termination of registration of a class of securities (Section 12(g))

Notice of Effectiveness

Notification of removal from listing and/or registration on a national securities exchange

Post-effective amendment to a registration statement

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Written communication about a business combination transaction (Rule 425)

Written communication about a business combination transaction (Rule 425)

Written communication about a business combination transaction (Rule 425)

Written communication about a business combination transaction (Rule 425)

Written communication about a business combination transaction (Rule 425)

Written communication about a business combination transaction (Rule 425)

Written communication about a business combination transaction (Rule 425)

Written communication about a business combination transaction (Rule 425)

Written communication about a business combination transaction (Rule 425)

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Written communication about a business combination transaction (Rule 425)

No description available

No description available

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Mendel Scott

Ramachandran Niro Ph.D

McKelligon Brian

Kamocsay Jennifer

Ek John Frederick

SHEPLER ROBERT G

BAMFORD PASCAL

Winkler Matthew

LAI GOLDMAN MYLA

Raffin Thomas A.

SCHNETTLER THOMAS P

BAMFORD PASCAL

Quanterix Corp

Akoya Biosciences, Inc.

Akoya Biosciences, Inc.

Ek John Frederick

McKelligon Brian

Ramachandran Niro Ph.D

BAMFORD PASCAL

McKelligon Brian

Annual Report Scanned (Paper)

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC

No description available

Correspondence with the SEC

Correspondence with the SEC

No description available

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

No description available

Draft registration statement (confidential submission) (amendment)

Letter from the SEC

Draft registration statement (confidential submission)